首站-论文投稿智能助手
典型文献
Risk factors for lymph node metastasis of cN0 papillary thyroid carcinoma
文献摘要:
Objective To investigate the risk factors for cervical lymph node metastasis of clinically lymph node-negative (cN0) papillary thyroid carcinoma (PTC). Methods Patients and Methods: The clinicopathologic data of patients with cN0 PTC who underwent at least one lobectomy plus central lymph node dissection at Xuzhou Central Hospital from January 2018 to December 2020 were retrospectively collected and the risk factors of lymph node metastasis analyzed. Univariate and multivariate analyses were performed to detect the risk factors for cervical lymph node metastasis. Results A total of 312 patients with cN0 PTC were enrolled in this study. The postoperative pathology results showed that 134 patients (42.9%) had central lymph node metastasis, of whom 24 (17.9%) had lateral lymph node metastasis (LLNM). The univariate analysis results showed that male gender, age <45 years, tumor diameter ≥10 mm, bilateral cancer, capsule invasion, and multiple foci were associated with cervical lymph node metastasis of cN0 PTC (P < 0.05). Further logistic regression analysis results showed that these factors, except age, were independent risk factors for cervical lymph node metastasis of cN0 PTC (P < 0.05). The results also showed that the risk of LLNM increased with an increase in the number of positive central lymph nodes in patients with cN0 PTC (P < 0.05). Conclusion Cervical lymph node metastasis of cN0 PTC is related to many factors, and a high number of positive central lymph nodes indicates a high risk of LLNM. Patients with risk factors should undergo preventive central lymph node dissection at the first surgery, and in patients with a high number of positive central lymph nodes, lateral lymph node dissection should be discreetly performed.
文献关键词:
作者姓名:
Guangcai Niu;Hao Guo
作者机构:
Department of Oncological Surgery,Xuzhou Central Hospital,Xuzhou 221000,China
引用格式:
[1]Guangcai Niu;Hao Guo-.Risk factors for lymph node metastasis of cN0 papillary thyroid carcinoma)[J].肿瘤学与转化医学(英文),2022(02):89-93
A类:
discreetly
B类:
Risk,factors,lymph,metastasis,cN0,papillary,thyroid,carcinoma,Objective,To,investigate,risk,cervical,clinically,negative,PTC,Methods,Patients,clinicopathologic,data,patients,underwent,least,one,lobectomy,plus,central,dissection,Xuzhou,Central,Hospital,from,January,December,were,retrospectively,collected,analyzed,Univariate,multivariate,analyses,performed,detect,Results,total,enrolled,this,study,postoperative,pathology,results,showed,that,had,whom,LLNM,univariate,analysis,male,gender,age,years,tumor,diameter,bilateral,cancer,capsule,invasion,multiple,foci,associated,Further,logistic,regression,these,except,independent,also,increased,number,positive,nodes,Conclusion,Cervical,related,many,high,indicates,should,undergo,preventive,first,surgery
AB值:
0.401146
相似文献
Development and evaluation of the screening performance of a low-cost high-risk screening strategy for breast cancer
Yubei Huang;Huan Wang;Zhangyan Lyu;Hongji Dai;Peifang Liu;Ying Zhu;Fengju Song;Kexin Chen-Department of Cancer Epidemiology and Biostatistics,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy of Tianjin,Tianjin's Clinical Research Center for Cancer,Key Laboratory of Cancer Molecular Epidemiology of Tianjin,Key Laboratory of Breast Cancer Prevention and Therapy,Ministry of Education,Tianjin 300060,China;Department of Breast Imaging,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy of Tianjin,Tianjin's Clinical Research Center for Cancer,Key Laboratory of Cancer Molecular Epidemiology of Tianjin,Key Laboratory of Breast Cancer Prevention and Therapy,Ministry of Education,Tianjin 300060,China
Prognostic and incremental value of computed tomography-based radiomics from tumor and nodal regions in esophageal squamous cell carcinoma
Bangrong Cao;Kun Mi;Wei Dai;Tong Liu;Tianpeng Xie;Qiang Li;Jinyi Lang;Yongtao Han;Lin Peng;Qifeng Wang-Radiation Oncology Key Laboratory of Sichuan Province Sichuan Cancer Hospital&Institute,Sichuan Cancer Center,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610041,China;Department of Biobank Sichuan Cancer Hospital&Institute,Sichuan Cancer Center,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610041,China;Department of Thoracic Surgery Sichuan Cancer Hospital&Institute,Sichuan Cancer Center,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610041,China;Department of Medical Imaging Sichuan Cancer Hospital&Institute,Sichuan Cancer Center,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610041,China;Department of Radiation Oncology,Sichuan Cancer Hospital&Institute,Sichuan Cancer Center,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610041,China
Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer: A pragmatic, multicenter, and prospective clinical trial in China
Binghe Xu;Huiping Li;Zefei Jiang;Lin Gu;Jinhai Tang;Hui Xie;Yueyin Pan;Yunjiang Liu;Shude Cui;Xiaojia Wang;Li Cai;Yiqiong Zhang;Huadong Zhao;Zhimin Shao-Department of Medical Oncology,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Breast Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Department of Breast Cancer,the Fifth Medical Center of Chinese PLA General Hospital,Beijing 100071,China;Department of Breast Cancer,Tianjin Cancer Institute and Hospital,Tianjin 300060,China;Department of Breast Cancer,Jiangsu Provincial Hospital,Nanjing 210029,China;Department of Breast Cancer,the First Affiliated Hospital of China University of Science and Technology,Hefei 230001,China;Department of Breast Cancer,the Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China;Department of Breast Cancer,Henan Cancer Hospital,Zhengzhou 450008,China;Department of Breast Cancer,Zhejiang Cancer Hospital,Hangzhou 310012,China;Department of Breast Cancer,Harbin Medical University Cancer Hospital,Harbin 150081,China;Department of Clinical Development,Pfizer(China)R&D Co.Ltd,Shanghai 201203,China;Department of Statistics,Pfizer(China)R&D Co.Ltd,Shanghai 201203,China;Department of Breast Surgery,Shanghai Cancer Center/Cancer Institute,Shanghai Medical College,Fudan University,Shanghai 200032,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。